Cardio Diagnostics Holdings reported revenue of $34,890 for fiscal year 2024, up from $17,065 in 2023, while maintaining a net loss of $8.38 million compared to $8.38 million in the previous year. Operating expenses increased to $8.4 million from $7.3 million, primarily due to higher general and administrative costs of $8.17 million, partially offset by reduced research and development spending.The company strengthened its financial position with cash and cash equivalents of $7.83 million as of December 31, 2024, compared to $1.28 million at the end of 2023. During the year, Cardio raised funds through an at-the-market offering and private placement, while expanding its product portfolio with the launch of HeartRisk™, a cardiovascular disease risk intelligence platform.The company continued to advance its commercialization strategy, securing partnerships with seven new provider organizations across multiple states and receiving Medicare pricing determination from CMS for its PrecisionCHD™ and Epi+Gen CHD™ tests. Looking ahead, Cardio plans to focus on developing additional products, expanding clinical evidence, and scaling internal operations while pursuing strategic partnerships.

Cardio Diagnostics Holdings reported revenue of $34,890 for fiscal year 2024, up from $17,065 in 2023, while maintaining a net loss of $8.38 million compared to $8.38 million in the previous year. Operating expenses increased to $8.4 million from $7.3 million, primarily due to higher general and administrative costs of $8.17 million, partially offset by reduced research and development spending.The company strengthened its financial position with cash and cash equivalents of $7.83 million as of December 31, 2024, compared to $1.28 million at the end of 2023. During the year, Cardio raised funds through an at-the-market offering and private placement, while expanding its product portfolio with the launch of HeartRisk™, a cardiovascular disease risk intelligence platform.The company continued to advance its commercialization strategy, securing partnerships with seven new provider organizations across multiple states and receiving Medicare pricing determination from CMS for its PrecisionCHD™ and Epi+Gen CHD™ tests. Looking ahead, Cardio plans to focus on developing additional products, expanding clinical evidence, and scaling internal operations while pursuing strategic partnerships.